Gossamer bio announces gb004 clinical trial data presentations at 2021 virtual congress of the european crohn's and colitis organisation

San diego--(business wire)--gossamer bio, inc. (nasdaq: goss), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will present data related to gb004 at the 2021 virtual congress of the european crohn's and colitis organisation (ecco), to be held virtually from july 2-3 and 8-10. on july 8, william sandborn, m.d., will present a digital ora
GOSS Ratings Summary
GOSS Quant Ranking